Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Clinical trial NCT03578367 · COMPLETED
Trial details
- NCT number
- NCT03578367
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-22
- Primary completion
- 2021-11-08
- Enrollment
- 104
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.